NovaBay Pharmaceuticals is a biotechnology company engaged in using its two distinct categories of product offerings – Aganocides and NeutroPhase Skin and Wound Cleanser – to address the large, unmet therapeutic needs of the worldwide anti-infective market. The company has four core business units that are developing treatments to tackle infections in the dermatology, urology, ophthalmology and wound care areas: DermaBay, UroBay, EyeBay and MediBay. For more information, visit the company’s Web site at www.novabaypharma.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: